MGC Pharmaceuticals Limited (MXC.AX)
| Previous close | 0.0130 |
| Open | 0.0120 |
| Bid | 0.0120 x 125665700 |
| Ask | 0.0130 x 8008500 |
| Day's range | 0.0120 - 0.0120 |
| 52-week range | 0.0120 - 0.0500 |
| Volume | |
| Avg. volume | 2,015,883 |
| Market cap | 34.39M |
| Beta (5Y monthly) | 1.58 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0080 |
| Earnings date | 26 Feb 2023 - 02 Mar 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.04 |
- PR Newswire
MGC Pharmaceuticals Successfully Developed Herbal-inspired Products for Treatment of Long COVID and COVID-19
MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), is a European based bio-pharma company, focused on developing and supplying affordable (Accessible) and Ethically Produced Plant Inspired Medicines, is helping to solve the mystery of treating Long COVID patients with a new herbal inspired medicine.
- PR Newswire
MGC Pharmaceuticals Enters Partnership with Sciensus Rare for Distribution of Cannabinoids to Treat Refractory Epilepsy, Dementia and Alzheimer's in the EU and UK
MGC Pharmaceuticals Ltd. (LSE: MXC, ASX: MXC, OTC:MGCLF), a European based bio-pharma company specializing in the production and development of phytomedicines, has signed an exclusive distribution agreement with Sciensus Rare, a part of UK health care group, Sciensus, for the distribution of CannEpil® and CogniCann® in key European territories and the UK.
- Simply Wall St.
Is MGC Pharmaceuticals (ASX:MXC) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
